Alagraf 0.5 Capsule

Alagraf 0.5 Capsule is used to treat eczema (atopic dermatitis). It works by suppressing the activity of certain immune cells that cause inflammation (redness and swelling) of the skin. This relieves itching and improves rashes in atopic dermatitis.

Alagraf 0.5 Capsule is used for external use. It should be used 2-4 times a day on the affected area or use it as suggested by the doctor. It should be applied slowly and evenly to the skin until it is rubbed in. You should not use it too often and you should not cover the treated area with a bandage or plaster. You must inform your doctor if there's no improvement even after two weeks of treatment or if the skin gets worse.

It is a safe medicine with few side effects, but you may get an application site reaction like burning, irritation, itching, and redness. This medicine is not normally recommended during pregnancy or while breastfeeding unless it is clearly needed.

• Prevention of organ rejection in transplant patients

Prevention of organ rejection in transplant patients
Alagraf 0.5 Capsule belongs to a group of medicines known as immunosuppressants. Organ rejection happens when your immune system treats the new organ as an invader and attacks it. This medicine weakens your immune response (which usually fights infection) and reduces the chance of your body attacking the transplanted organ. It is used in combination with other medicines to make it much more likely that your transplant operation will be successful. You should continue taking the medicine and should not stop it until your doctor says so.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Tacrofine

• Application site reactions (burning, irritation, itching and redness)
• Diarrhea
• Increased glucose level in blood
• Increased thirst
• Kidney damage
• Liver damage
• Nausea
• Stomach pain

This medicine is for external use only. Use it in the dose and duration as advised by your doctor. Check the label for directions before use. Clean and dry the affected area and gently massage the ointment.

Alagraf 0.5 Capsule is an immunosuppressant. It works by suppressing the activity of certain immune cells that cause inflammation (redness and swelling) of the skin. This relieves itching and improves rashes in atopic dermatitis.

• Alagraf 0.5 Capsule is effective at treating eczema (atopic dermatitis) when other treatment options have failed.
• It works by decreasing itching, redness, and skin rashes.
• Apply thinly, to affected areas of skin only. Clean the affected area and dry well before applying Alagraf 0.5 Capsule. Avoid contact with water after application.
• Inform your doctor if there's no improvement even after two weeks of treatment, or if the skin gets worse.
• Don't cover the area being treated with airtight dressings such as bandages unless directed by a doctor, as this may increase the risk of side effects.
• Stop using Alagraf 0.5 Capsule and consult your doctor if your eczema becomes infected.
• Continuous long-term use of the ointment should be avoided. Use as prescribed by you doctor.

Burkhart C, Morrell D, Goldsmith L. Dermatological Pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 1822.

Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 972.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1305-309.

Tacrolimus monohydrate. Hurley, Berkshire: Leo Laboratories Limited; 2002 [revised 30 Jun. 2018]. [Accessed 17 Apr. 2019] (online) Available from:

Central Drugs Standard Control Organisation (CDSCO). [Accessed 06 Apr. 2019] (online) Available from: